Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 72
Filter
1.
Nutr Neurosci ; 23(6): 471-480, 2020 Jun.
Article in English | MEDLINE | ID: mdl-30207204

ABSTRACT

Polyphenols are shown to protect from or delay the progression of chronic neurodegenerative diseases. Mitochondrial dysfunction plays a key role in the pathogenesis of Parkinson's disease (PD). This study was aims to gain insight into the role of ahydroalcoholic extract of cocoa (standardised for epicatechin content) on mitochondrial biogenesis in MPP+ intoxicated human neuroblastoma cells (SHSY5Y). The effects of cocoa on PPARγ, PGC1α, Nrf2 and TFAM protein expression and mitochondrial membrane potential were evaluated. A pre-exposure to cocoa extract decreased reactive oxygen species formation and restored mitochondrial membrane potential. The cocoa extract was found to up-regulate the expression of PPARγ and the downstream signalling proteins PGC1α, Nrf2 and TFAM. It increased the expression of the anti-apoptotic protein BCl2 and increased superoxide dismutase activity. Further, the cocoa extract down-regulated the expression of mitochondria fission 1 (Fis1) and up-regulated the expression of mitochondria fusion 2 (Mfn2) proteins, suggesting an improvement in mitochondrial functions in MPP+ intoxicated cells upon treatment with cocoa. Interestingly, cocoa up-regulates the expression of tyrosine hydroxylase, the rate limiting enzyme in dopamine synthesis. No change in the expression of PPARγ on treatment with cocoa extract was observed when the cells were pre-treated with PPARγ antagonist GW9662. This data suggests that cocoa mediates mitochondrial biogenesis via a PPARγ/PGC1α dependent signalling pathway and also has the ability to improve dopaminergic functions by increasing tyrosine hydroxylase expression. Based on our data, we propose that a cocoa bean extract and products thereof could be used as potential nutritional supplements for neuroprotection in PD.


Subject(s)
Cacao , Mitochondria/drug effects , Mitochondria/metabolism , Organelle Biogenesis , PPAR gamma/metabolism , Parkinson Disease/metabolism , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism , Plant Extracts/administration & dosage , Cell Line, Tumor , Humans , Membrane Potential, Mitochondrial/drug effects , Mitochondrial Dynamics/drug effects , Parkinson Disease/prevention & control , Reactive Oxygen Species/metabolism , Signal Transduction/drug effects
3.
Neurochem Res ; 44(11): 2684, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31628643

ABSTRACT

The original version of this article unfortunately contains an error in Fig. 2a (4th image for walnut). This has been corrected by publishing this erratum.

4.
Nutr Neurosci ; 21(2): 97-107, 2018 Feb.
Article in English | MEDLINE | ID: mdl-27646574

ABSTRACT

The present study was aimed to find out the effect of Agaricus blazei mushroom extract against rotenone-induced cellular model. SH-SY5Y neuroblastoma cells are divided into four experimental groups (control, rotenone (100 nM), A. blazei (5 µg/ml) + rotenone (100 nM), and A. blazei alone treated) based on MTT assay, cells were allowed to measure the ROS, TBARS levels, and antioxidants activities. Finally, mitochondrial transmembrane potential (MMP) and expressions of apoptotic proteins were also analyzed. Pre-treatment with A. blazei significantly enhanced cell viability, attenuated rotenone-induced ROS, MMP, and apoptosis. Our results indicated that anti-apoptotic properties of this natural compound due to its antioxidant and mitochondrial protective function protect rotenone-induced cytotoxicity. Therefore, it may be concluded that A. blazei can be further developed as a promising drug for the treatment of Parkinson's disease (PD).


Subject(s)
Agaricus/chemistry , Antioxidants/pharmacology , Apoptosis/drug effects , Mitochondria/drug effects , Rotenone/toxicity , Agaricales/chemistry , Apoptosis Regulatory Proteins/genetics , Apoptosis Regulatory Proteins/metabolism , Cell Line, Tumor , Cell Survival/drug effects , Glutathione/metabolism , Humans , Membrane Potential, Mitochondrial/drug effects , Mitochondria/metabolism , Neuroblastoma/drug therapy , Oxidative Stress/drug effects , Parkinson Disease , Reactive Oxygen Species/metabolism , Superoxide Dismutase/metabolism , Thiobarbituric Acid Reactive Substances/metabolism
5.
Nutr Neurosci ; 21(9): 657-666, 2018 Nov.
Article in English | MEDLINE | ID: mdl-28628424

ABSTRACT

Neuroinflammation and oxidative damage are the two main malfactors that play an important role in the pathogenesis of experimental and clinical Parkinson's disease (PD). The current study was aimed to study the possible anti-oxidant and anti-inflammatory effects of the methanolic extract of Agaricus blazei (A. blazei) against rotenone-induced PD in mice. Male Albino mice were randomized and divided into the following groups: control, treated with rotenone (1 mg/kg/day), co-treated with rotenone and A. blazei (50, 100, and 200 mg/kg b.w.), and treated with A. blazei alone (200 mg/kg b.w.). After the end of the experimental period, behavioral studies, biochemical estimations, and protein expression patterns of inflammatory markers were studied. Rotenone treatment exhibited enhanced motor impairments, neurochemical deficits, oxidative stress, and inflammation, whereas oral administration of A. blazei extract attenuated the above-said indices. Even though further research is needed to prove its efficacy in clinical studies, the results of our study concluded that A. blazei extract offers a promising and new therapeutic lead for treatment of PD.


Subject(s)
Agaricus/chemistry , Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , Dopamine/metabolism , Parkinson Disease, Secondary/drug therapy , Animals , Catalase/metabolism , Dopamine/deficiency , Glutathione/analysis , Glutathione Peroxidase/metabolism , Male , Mice , Mitochondria/metabolism , Oxidative Stress/drug effects , Rotenone/toxicity , Superoxide Dismutase/metabolism , Thiobarbituric Acid Reactive Substances/analysis
7.
Neurochem Res ; 42(5): 1354-1365, 2017 May.
Article in English | MEDLINE | ID: mdl-28181071

ABSTRACT

Regulation of various signalling (Ras-MAPK, PI3K and AKT) pathways by augmented activity of neurotrophic factors (NTFs) could prevent or halt the progress of dopaminergic loss in Parkinson's disease (PD). Various in vitro and in vivo experimental studies indicated anti-parkinsonic potential of asiatic acid (AA), a pentacyclic triterpene obtained from Centella asiatica. So the present study is designed to determine the neurotrophic effect of AA against 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine hydrochloride/probenecid (MPTP/p) neurotoxicity in mice model of PD. AA treatment for 5 weeks significantly attenuated MPTP/p induced motor abnormalities, dopamine depletion and diminished expressions NTFs and tyrosine kinase receptors (TrKB). We further, revealed that AA treatment significantly inhibited the MPTP/p-induced phosphorylation of MAPK/P38 related proteins such as JNK and ERK. Moreover, AA treatment increased the phosphorylation of PI3K, Akt, GSK-3ß and mTOR, suggesting that AA activated PI3K/Akt/mTOR signalling pathway, which might be the cause of neuroprotection offered by AA. The present findings provided more elaborate in vivo evidences to support the neuroprotective effect of AA on dopaminergic neurons of chronic Parkinson's disease mouse model and the potential of AA to be developed as a possible new therapeutic target to treat PD.


Subject(s)
MPTP Poisoning/metabolism , MPTP Poisoning/prevention & control , Mitogen-Activated Protein Kinase Kinases/metabolism , Pentacyclic Triterpenes/therapeutic use , Probenecid/toxicity , TOR Serine-Threonine Kinases/metabolism , Animals , Glycogen Synthase Kinase 3 beta/antagonists & inhibitors , Glycogen Synthase Kinase 3 beta/metabolism , MPTP Poisoning/chemically induced , Male , Mice , Mice, Inbred C57BL , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Oncogene Protein v-akt/antagonists & inhibitors , Oncogene Protein v-akt/metabolism , Pentacyclic Triterpenes/pharmacology , Phosphatidylinositol 3-Kinases/metabolism , Phosphoinositide-3 Kinase Inhibitors , TOR Serine-Threonine Kinases/antagonists & inhibitors , Treatment Outcome
8.
Nutr Neurosci ; 20(6): 351-359, 2017 Jul.
Article in English | MEDLINE | ID: mdl-26856988

ABSTRACT

Parkinson's disease (PD) is a chronic neurodegenerative disease, manifested due to the loss of dopaminergic neurons, which ultimately leads to impaired movement in elderly populations. The pathogenesis of PD is associated with numerous factors including oxidative stress, mitochondrial dysfunction and apoptosis. There is no effective therapy available to cure or halt the progression of this disease still now. Asiatic acid (AA) is a triterpene extracted from Centella asiatica has been reported as an antioxidant and anti-inflammatory agent, that offers neuroprotection against glutamate toxicity. Therefore, in this study, we have investigated the effect of AA in a rotenone (an inhibitor of mitochondrial complex I) induced in vitro model of PD. Following the exposure of SH-SY5Y cells to rotenone, there was a marked overproduction of ROS, mitochondrial dysfunction (as indexed by the decrease in mitochondrial membrane potential) and apoptosis (Hoechst and dual staining, comet assay; expressions of pro-apoptotic and anti-apoptotic indices). Pre-treatment with AA reversed these changes might be due to its antioxidant, mitoprotective and anti-apoptotic properties. However further extensive studies on in vivo models of PD are warranted to prove AA neuroprotective effect before entering into the clinical trial.


Subject(s)
Apoptosis/drug effects , Drugs, Investigational/pharmacology , Mitochondria/drug effects , Neurons/drug effects , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Pentacyclic Triterpenes/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antioxidants/pharmacology , Antiparkinson Agents/pharmacology , Apoptosis Regulatory Proteins/agonists , Apoptosis Regulatory Proteins/antagonists & inhibitors , Apoptosis Regulatory Proteins/metabolism , Biomarkers/metabolism , Cell Line, Tumor , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Nucleus/pathology , Cell Survival/drug effects , DNA Damage/drug effects , Humans , Membrane Potential, Mitochondrial/drug effects , Mitochondria/metabolism , Mitochondria/pathology , Nerve Tissue Proteins/agonists , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/metabolism , Neurons/cytology , Neurons/metabolism , Neurons/pathology , Reactive Oxygen Species/agonists , Reactive Oxygen Species/antagonists & inhibitors , Reactive Oxygen Species/metabolism , Rotenone/toxicity , Uncoupling Agents/toxicity
9.
Nutr Neurosci ; 20(6): 360-368, 2017 Jul.
Article in English | MEDLINE | ID: mdl-26878879

ABSTRACT

BACKGROUND/AIMS: Deregulation of metal ion homeostasis has been assumed as one of the key factors in the progression of neurodegenerative diseases. Aluminium (Al) has been believed as a major risk factor for the cause and progression of Alzheimer's disease (AD). In our lab, we have previously reported that hesperidin, a citrus bioflavonoid reversed memory loss caused by aluminium intoxication through attenuating acetylcholine esterase activity and the expression of Amyloid ß biosynthesis related markers. Al has been reported to cause oxidative stress associated apoptotic neuronal loss in the brain. So in the present study, protective effect of hesperidin against aluminium chloride (AlCl3) induced cognitive impairment, oxidative stress and apoptosis was studied. METHODS: Male Wistar rats were divided into control, AlCl3 treated (100 mg/kg., b.w.), AlCl3 and hesperidin (100 mg/kg., b.w.) co-treated and hesperidin alone treated groups. In control and experimental rats, learning and memory impairment were measured by radial arm maze, elevated plus maze and passive avoidance tests. In addition, oxidative stress and expression of pro and anti-apoptotic markers were also evaluated. RESULTS: Intraperitoneal injection of AlCl3 (100 mg/kg., b.w.) for 60 days significantly enhanced the learning and memory deficits, levels of thiobarbituric acid reactive substances and the expression of Bax and diminished the levels of reduced glutathione, activities of enzymatic antioxidants and the expression of B-cell lymphoma-2 (Bcl-2) as compared to control group in the hippocampus, cortex, and cerebellum. Coadministration of hesperidin (100 mg/kg., b.w. oral) for 60 days prevented the cognitive deficits, biochemical anomalies and apoptosis induced by AlCl3 treatment. CONCLUSION: Results of the present study demonstrated that hesperidin could be a potential therapeutic agent in the treatment of oxidative stress and apoptosis associated neurodegenerative diseases including AD.


Subject(s)
Alzheimer Disease/prevention & control , Antioxidants/therapeutic use , Dietary Supplements , Disease Models, Animal , Hesperidin/therapeutic use , Neuroprotective Agents/therapeutic use , Nootropic Agents/therapeutic use , Aluminum Chloride , Aluminum Compounds , Alzheimer Disease/metabolism , Animals , Apoptosis , Apoptosis Regulatory Proteins/agonists , Apoptosis Regulatory Proteins/antagonists & inhibitors , Apoptosis Regulatory Proteins/metabolism , Avoidance Learning , Cerebellum/metabolism , Cerebral Cortex/metabolism , Chlorides , Hippocampus/metabolism , Male , Maze Learning , Nerve Tissue Proteins/agonists , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Oxidative Stress , Random Allocation , Rats, Wistar
10.
Nutr Neurosci ; 20(1): 40-48, 2017 Jan.
Article in English | MEDLINE | ID: mdl-25238165

ABSTRACT

BACKGROUND: Seed oils are used as cosmetics or topical treatment for wounds, allergy, dandruff, and other purposes. Natural antioxidants from plants were recently reported to delay the onset or progress of various neurodegenerative conditions. Over one thousand cultivars of Punica granatum (Punicaceae) are known and some are traditionally used to treat various ailments. AIM: The effect of pomegranate oil on 3-nitropropionic acid- (3-NP) induced cytotoxicity in rat pheochromocytoma (PC12) neuronal cells was analyzed in this study. Furthermore, the analysis of unsaturated fatty acid composition of the seed oil of pomegranate by gas chromatography-electron impact mass spectrometry (GC-MS) was done. RESULTS: GC-MS study showed the presence of 6,9-octadecadiynoic acid (C18:2(6,9)) as a major component (60%) as 4,4-dimethyloxazoline derivative. The total extractable oil with light petroleum ether by Soxhlet from the dry seed of P. granatum was 4-6%. The oil analyzed for 48.90 ±â€Š1.50 mg gallic acid equivalents/g of oil, and demonstrated radical-scavenging-linked antioxidant activities in various in vitro assays like the DPPH (2,2-diphenyl-l-picrylhydrazyl, % IP = 35.2 ± 0.9%), ABTS (2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid), % IP 2.2 ± 0.1%), and ß-carotene bleaching assay (% IP = 26 ± 3%), respectively, which could be due the possible role of one methylene interrupted diynoic acid system for its radical-scavenging/antioxidant properties of oil. The oil also reduced lipid peroxidation, suppressed reactive oxygen species, extracellular nitric oxide, lactate/pyruvate ratio, and lactase dehydrogenase generated by 3-NP- (100 mM) induced neurotoxicity in PC12 cells, and enhanced the levels of enzymatic and non-enzymatic antioxidants at 40 µg of gallic acid equivalents. CONCLUSION: The protective effect of pomegranate seed oil might be due to the ability of an oil to neutralize ROS or enhance the expression of antioxidant gene and the exact mechanism of action yet to be elucidated.


Subject(s)
Lythraceae/chemistry , Neurons/drug effects , Neuroprotective Agents/metabolism , Oxidative Stress , Plant Oils/metabolism , Seeds/chemistry , Animals , Antioxidants/chemistry , Antioxidants/metabolism , Antioxidants/therapeutic use , Cell Line, Tumor , Cell Survival/drug effects , Dietary Supplements/analysis , Ethnopharmacology , Linoleic Acids/analysis , Lipid Peroxidation/drug effects , Lythraceae/growth & development , Medicine, Traditional , Neurons/metabolism , Neuroprotective Agents/chemistry , Neuroprotective Agents/therapeutic use , Neurotoxicity Syndromes/prevention & control , Nitro Compounds/antagonists & inhibitors , Nitro Compounds/toxicity , Oman , Oxazoles/analysis , Oxidants/antagonists & inhibitors , Oxidants/toxicity , Oxidative Stress/drug effects , Plant Oils/chemistry , Plant Oils/therapeutic use , Propionates/antagonists & inhibitors , Propionates/toxicity , Rats , Reactive Oxygen Species/antagonists & inhibitors , Reactive Oxygen Species/metabolism , Seeds/growth & development
11.
BMC Complement Altern Med ; 17(1): 217, 2017 Apr 18.
Article in English | MEDLINE | ID: mdl-28420370

ABSTRACT

BACKGROUND: Mitochondrial dysfunction and oxidative stress are the main toxic events leading to dopaminergic neuronal death in Parkinson's disease (PD) and identified as vital objective for therapeutic intercession. This study investigated the neuro-protective effects of the demethoxycurcumin (DMC), a derivative of curcumin against rotenone induced neurotoxicity. METHODS: SH-SY5Y neuroblastoma cells are divided into four experimental groups: untreated cells, cells incubated with rotenone (100 nM), cells treated with DMC (50 nM) + rotenone (100 nM) and DMC alone treated. 24 h after treatment with rotenone and 28 h after treatment with DMC, cell viability was assessed using the MTT assay, and levels of ROS and MMP, plus expression of apoptotic protein were analysed. RESULTS: Rotenone induced cell death in SH-SY5Y cells was significantly reduced by DMC pretreatment in a dose-dependent manner, indicating the potent neuroprotective effects of DMC. Rotenone treatment significantly increases the levels of ROS, loss of MMP, release of Cyt-c and expression of pro-apoptotic markers and decreases the expression of anti-apoptotic markers. CONCLUSIONS: Even though the results of the present study indicated that the DMC may serve as a potent therapeutic agent particularly for the treatment of neurodegenerative diseases like PD, further pre-clinical and clinical studies are required.


Subject(s)
Curcumin/analogs & derivatives , Membrane Potential, Mitochondrial/drug effects , Neuroprotective Agents/pharmacology , Neurotoxicity Syndromes/metabolism , Oxidative Stress/drug effects , Plant Extracts/pharmacology , Rotenone/toxicity , Cell Death , Cell Line, Tumor , Cell Survival , Curcuma/chemistry , Curcumin/pharmacology , Curcumin/therapeutic use , Cytochromes c/metabolism , Diarylheptanoids , Dopaminergic Neurons/drug effects , Humans , Insecticides/toxicity , Neuroprotective Agents/therapeutic use , Neurotoxicity Syndromes/drug therapy , Parkinson Disease/drug therapy , Parkinson Disease/metabolism , Phytotherapy , Plant Extracts/therapeutic use , Reactive Oxygen Species/metabolism
12.
Neurochem Res ; 41(8): 1899-910, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27038927

ABSTRACT

Vanillin (4-hydroxy-3-methoxybenzaldehyde), a pleasant smelling organic aromatic compound, is widely used as a flavoring additive in food, beverage, cosmetic and drug industries. It is reported to cross the blood brain barrier and also displayed antioxidant and neuroprotective activities. We previously reported the neuroprotective effect of vanillin against rotenone induced in in vitro model of PD. The present experiment was aimed to analyze the neuroprotective effect of vanillin on the motor and non-motor deficits, neurochemical variables, oxidative, anti-oxidative indices and the expression of apoptotic markers against rotenone induced rat model of Parkinson's disease (PD). Rotenone treatment exhibited motor and non-motor impairments, neurochemical deficits, oxidative stress and apoptosis, whereas oral administration of vanillin attenuated the above-said indices. However further studies are needed to explore the mitochondrial protective and anti-inflammatory properties of vanillin, as these processes play a vital role in the cause and progression of PD.


Subject(s)
Antioxidants/therapeutic use , Apoptosis/drug effects , Benzaldehydes/therapeutic use , Mental Disorders/drug therapy , Oxidative Stress/drug effects , Parkinsonian Disorders/drug therapy , Rotenone/toxicity , Animals , Antioxidants/pharmacology , Apoptosis/physiology , Benzaldehydes/pharmacology , Dose-Response Relationship, Drug , Male , Maze Learning/drug effects , Maze Learning/physiology , Mental Disorders/chemically induced , Mental Disorders/metabolism , Oxidative Stress/physiology , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/metabolism , Rats , Rats, Wistar
13.
Nutr Neurosci ; 19(6): 237-46, 2016 Jul.
Article in English | MEDLINE | ID: mdl-25730317

ABSTRACT

OBJECTIVE: Mitochondrial dysfunction and oxidative stress-mediated apoptosis plays an important role in various neurodegenerative diseases including Huntington's disease, Parkinson's disease (PD) and Alzheimer's disease (AD). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the most widely used neurotoxin mimics the symptoms of PD by inhibiting mitochondrial complex I that stimulates excessive intracellular reactive oxygen species (ROS) and finally leads to mitochondrial-dependent apoptosis. Lutein, a carotenoid of xanthophyll family, is found abundantly in leafy green vegetables such as spinach, kale and in egg yolk, animal fat and human eye retinal macula. Increasing evidence indicates that lutein has offers benefits against neuronal damages during diabetic retinopathy, ischemia and AD by virtue of its mitochondrial protective, antioxidant and anti-apoptotic properties. METHODS: Male C57BL/6 mice (23-26 g) were randomized and grouped in to Control, MPTP, and Lutein treated groups. RESULTS: Lutein significantly reversed the loss of nigral dopaminergic neurons by increasing the striatal dopamine level in mice. Moreover, lutein-ameliorated MPTP induced mitochondrial dysfunction, oxidative stress and motor abnormalities. In addition, lutein repressed the MPTP-induced neuronal damage/apoptosis by inhibiting the activation of pro-apoptotic markers (Bax, caspases-3, 8 and 9) and enhancing anti-apoptotic marker (Bcl-2) expressions. DISCUSSION: Our current results revealed that lutein possessed protection on dopaminergic neurons by enhancing antioxidant defense and diminishing mitochondrial dysfunction and apoptotic death, suggesting the potential benefits of lutein for PD treatment.


Subject(s)
Apoptosis , Dietary Supplements , Dopaminergic Neurons/metabolism , Lutein/therapeutic use , Mitochondria/metabolism , Neuroprotective Agents/therapeutic use , Parkinson Disease/prevention & control , Animals , Antiparkinson Agents/administration & dosage , Antiparkinson Agents/adverse effects , Antiparkinson Agents/therapeutic use , Apoptosis/drug effects , Apoptosis Regulatory Proteins/agonists , Apoptosis Regulatory Proteins/antagonists & inhibitors , Apoptosis Regulatory Proteins/metabolism , Behavior, Animal/drug effects , Biomarkers/metabolism , Dietary Supplements/adverse effects , Dopamine/chemistry , Dopamine/metabolism , Dopaminergic Neurons/drug effects , Lutein/administration & dosage , Lutein/adverse effects , MPTP Poisoning/etiology , MPTP Poisoning/metabolism , MPTP Poisoning/physiopathology , Male , Mice, Inbred C57BL , Mitochondria/drug effects , Motor Activity/drug effects , Nerve Tissue Proteins/agonists , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/metabolism , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/adverse effects , Oxidative Stress/drug effects , Parkinson Disease/etiology , Parkinson Disease/metabolism , Random Allocation , Substantia Nigra/drug effects , Substantia Nigra/metabolism
14.
Nutr Neurosci ; 19(6): 269-78, 2016 Jul.
Article in English | MEDLINE | ID: mdl-25842984

ABSTRACT

BACKGROUND/AIMS: Emblica officinalis is mentioned as a maharasayana in many Ayurvedic texts and promotes intelligence, memory, freedom from disease, longevity, and strength of the senses. The present study has been designed to explore the memory-enhancing effect of the tannoid principles of E. officinalis (EoT) at the biochemical, anatomical, behavioral, and molecular levels against aluminum chloride (AlCl3) induced Alzheimer's disease (AD) in rats. Aluminum is reported to have an important role in the etiology, pathogenesis, and development of AD. METHODS: Male Wistar rats were divided into control, AlCl3 treated, AlCl3 and EoT (50, 100, and 200 mg/kg bw) co-treated, and EoT (200 mg/kg bw) alone treated groups. In control and experimental rats, behavior tests including water maze and open field test, estimation of aluminum, assay of acetylcholinesterase (AChE) activity, and expression of amyloidogenic proteins were performed. RESULTS: Intraperitonial injection of AlCl3 (100 mg/kg bw) for 60 days significantly elevated the concentration of aluminum (Al), activity of AChE and protein expressions of amyloid precursor protein, A-beta1-42, beta-, and gamma-secretases as compared to control group in hippocampus and cortex. Co-administration of EoT orally to AlCl3 rats for 60 days significantly revert back the Al concentration, AChE activity, and A-beta synthesis-related molecules in the studied brain regions. The spatial learning, memory, and locomotor impairments observed in AlCl3 treated rats were significantly attenuated by EoT. CONCLUSION: Therefore, EoT may be a promising therapy in ameliorating neurotoxicity of aluminum, however further studies are warranted to elucidate the exact mechanism of action of EoT.


Subject(s)
Alzheimer Disease/prevention & control , Cognitive Dysfunction/prevention & control , Disease Models, Animal , Neuroprotective Agents/therapeutic use , Phyllanthus emblica/chemistry , Plant Extracts/therapeutic use , Plaque, Amyloid/prevention & control , Aluminum Chloride , Aluminum Compounds , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Animals , Biomarkers/metabolism , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Chlorides , Cognitive Dysfunction/etiology , Dietary Supplements/analysis , Ethnopharmacology , Fruit/chemistry , Hippocampus/metabolism , Hippocampus/pathology , Male , Medicine, Ayurvedic , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Neurons/pathology , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/adverse effects , Neuroprotective Agents/chemistry , Plant Extracts/administration & dosage , Plant Extracts/adverse effects , Plant Extracts/chemistry , Plaque, Amyloid/etiology , Random Allocation , Rats, Wistar , Tannins/administration & dosage , Tannins/adverse effects , Tannins/analysis , Tannins/therapeutic use
15.
Neurochem Res ; 40(4): 767-76, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25630717

ABSTRACT

The present study was aimed to evaluate the protective effect of hesperidin (Hes) on aluminium chloride (AlCl3) induced neurobehavioral and pathological changes in Alzheimeric rats. Intraperitonial injection of AlCl3 (100 mg/kg body weight) for 60 days significantly elevated the levels of aluminium (Al), activity of acetylcholinesterase (AChE) and protein expressions of amyloid precursor protein (APP), ß amyloid (Aß 1-42), ß and γ secretases as compared to control group in hippocampus and cortex of rat brain. Hes administration orally along with AlCl3 injection for 60 days, significantly revert the Al concentration, AChE activity and Aß synthesis-related molecules in the studied brain regions. Our results showed that aluminum exposure was significantly reduced the spontaneous locomotor and exploratory activities in open field test and enhanced the learning and memory impairments in morris water maze test. The behavioral impairments caused by aluminum were significantly attenuated by Hes. The histopathological studies in the hippocampus and cortex of rat brain also supported that Hes (100 mg/kg) markedly reduced the toxicity of AlCl3 and preserved the normal histoarchitecture pattern of the hippocampus and cortex. From these results, it is concluded that hesperidin can reverse memory loss caused by aluminum intoxication through attenuating AChE activity and amyloidogenic pathway.


Subject(s)
Aluminum Compounds/toxicity , Alzheimer Disease/prevention & control , Chlorides/toxicity , Hesperidin/pharmacology , Neuroprotective Agents/pharmacology , Aluminum Chloride , Alzheimer Disease/chemically induced , Animals , Behavior, Animal , Male , Rats , Rats, Wistar
16.
Neurochem Res ; 40(6): 1283-93, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25944473

ABSTRACT

Numerous studies indicating that natural plant sources and their active phytochemicals offer protection to the pathological processes related to the development of neurogenerative diseases including Parkinson's disease (PD). In the present study, the neuro protective efficacy of dietary supplementation of walnut (6 %) for 28 days was examined in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (i.p., 20 mg/kg body weight/day) for last four consecutive days. MPTP injection diminished the levels of GSH, dopamine and metabolites along with decreased activities of GPx and mitochondrial complex I. Further, the levels of TBARS and enzymatic antioxidants such as SOD and catalase, MAO-B activities were enhanced by MPTP treatment. Behavioral deficits and lowered TH expression are also proved MPTP induced neurotoxicity. Dietary supplementation of walnut attenuated MPTP-induced impairment in PD mice might be by its MAO-B inhibitory, antioxidant and mitochondrial protective actions. To find out the exact mechanism of action walnut on PD mice warrants further extensive studies.


Subject(s)
Dietary Supplements , Juglans/chemistry , MPTP Poisoning/drug therapy , Parkinsonian Disorders/drug therapy , Plant Extracts/therapeutic use , Animals , Antioxidants/pharmacology , Behavior, Animal/drug effects , Dopamine/metabolism , Electron Transport Complex I/drug effects , Glutathione/metabolism , MPTP Poisoning/psychology , Mice , Monoamine Oxidase Inhibitors/pharmacology , Neuroprotective Agents/pharmacology , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/psychology , Plant Extracts/chemistry , Plant Extracts/pharmacology , Tyrosine 3-Monooxygenase/metabolism
17.
Neurochem Res ; 39(4): 668-76, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24493626

ABSTRACT

In the present study, using a human neuroblastoma SK-N-SH cells, we explored antioxidant, mitochondrial protective and antiapoptotic properties of mangiferin against rotenone-mediated cytotoxicity. SK-N-SH cells are divided into four experimental groups based on 3-(4,5-dimethyl2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay-untreated cells, cells incubated with rotenone (100 nM), cells treated with mangiferin (20 µg) (pretreatment 4 h before) + rotenone (100 nM) and mangiferin alone treated. 24 h after treatment with rotenone and 28 h after treatment with mangiferin, levels of ATP thiobarbituricacid reactive substances and reduced glutathione and activities of enzymatic antioxidants including superoxide dismutase, catalase and glutathione peroxidise were measured. Finally mitochondrial transmembrane potential and expressions of apoptotic protein were also analysed. Pre-treatment with mangiferin significantly enhanced cell viability, ameliorated decrease in mitochondrial membrane potential and decreased rotenone-induced apoptosis in the cellular model of Parkinson's disease. Moreover oxidative imbalance induced by rotenone was partially rectified by mangiferin. Our results indicated that anti-apoptotic properties of this natural compound due to its antioxidant and mitochondrial protective function protect rotenone induced cytotoxicity.


Subject(s)
Apoptosis/physiology , Mitochondria/metabolism , Neuroblastoma/metabolism , Oxidative Stress/physiology , Rotenone/toxicity , Xanthones/pharmacology , Apoptosis/drug effects , Cell Line, Tumor , Dose-Response Relationship, Drug , Humans , Membrane Potential, Mitochondrial/drug effects , Membrane Potential, Mitochondrial/physiology , Mitochondria/drug effects , Neuroblastoma/drug therapy , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Oxidative Stress/drug effects , Rotenone/antagonists & inhibitors , Xanthones/therapeutic use
18.
J Pineal Res ; 55(3): 304-12, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23952687

ABSTRACT

The dopamine precursor, L-3,4-dihydroxyphenylalanine (L-DOPA), is the preferred drug for Parkinson's disease, but long-term treatment results in the drug-induced dyskinesias and other side effects. This study was undertaken to examine whether melatonin could potentiate low dose L-DOPA effects in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental parkinsonism. Mice were treated with the parkinsonian neurotoxin, MPTP, and different doses of melatonin and low doses of L-DOPA. Behavior, striatal histology, and dopamine metabolism were evaluated on the 7th day. MPTP-induced striatal dopamine loss was not modified by melatonin administration (10-30 mg/kg; i.p. at 10-hr intervals, 6 times; or at 2-hr intervals, by day). However, low doses of L-DOPA (5 mg/kg, by oral gavage) administered alone or along with melatonin (10 mg/kg, i.p.) twice everyday for 2 days, 10 hr apart, after two doses of MPTP significantly attenuated striatal dopamine loss and provided improvements in both catalepsy and akinesia. Additionally, Golgi-impregnated striatal sections showed preservation of the medium spiny neurons, which have been damaged in MPTP-treated mouse. The results demonstrated that melatonin, but not L-DOPA, restored spine density and spine morphology of medium spiny neurons in the striatum and suggest that melatonin could be an ideal adjuvant to L-DOPA therapy in Parkinson's disease, and by the use of this neurohormone, it is possible to bring down the therapeutic doses of L-DOPA.


Subject(s)
Antiparkinson Agents/pharmacology , Central Nervous System Depressants/pharmacology , Corpus Striatum/metabolism , Dendrites/metabolism , Levodopa/pharmacology , Melatonin/pharmacology , Parkinson Disease, Secondary/drug therapy , Animals , Antiparkinson Agents/agonists , Central Nervous System Depressants/agonists , Corpus Striatum/pathology , Dendrites/pathology , Dopamine/metabolism , Dose-Response Relationship, Drug , Drug Synergism , Levodopa/agonists , MPTP Poisoning/drug therapy , MPTP Poisoning/metabolism , MPTP Poisoning/pathology , Melatonin/agonists , Mice , Mice, Inbred BALB C , Parkinson Disease, Secondary/metabolism , Parkinson Disease, Secondary/pathology
19.
J Microbiol Biotechnol ; 31(6): 867-874, 2021 Jun 28.
Article in English | MEDLINE | ID: mdl-33820886

ABSTRACT

Epalrestat (EPS) is a brain penetrant aldose reductase inhibitor, an approved drug currently used for the treatment of diabetic neuropathy. At near-plasma concentration, EPS induces glutathione biosynthesis, which in turn reduces oxidative stress in the neuronal cells. In this study, we found that EPS reduces neurodegeneration by inhibiting reactive oxygen species (ROS)-induced oxidative injury, mitochondrial membrane damage, apoptosis and tauopathy. EPS treatment up to 50 µM did not show any toxic effect on SH-SY5Y cell line (neuroblastoma cells). However, we observed toxic effect at a concentration of 100 µM and above. At 50 µM concentration, EPS showed better antioxidant activity against H2O2 (100 µM)-induced cytotoxicity, ROS formation and mitochondrial membrane damage in retinoic acid-differentiated SH-SY5Y cell line. Furthermore, our study revealed that 50 µM of EPS concentration reduced the glycogen synthase kinase-3 ß (GSK3-ß) expression and total tau protein level in H2O2 (100 µM)-treated cells. Findings from this study confirms the therapeutic efficacy of EPS on regulating Alzheimer's disease (AD) by regulating GSK3-ß and total tau proteins phosphorylation, which helped to restore the cellular viability. This process could also reduce toxic fibrillary tangle formation and disease progression of AD. Therefore, it is our view that an optimal concentration of EPS therapy could decrease AD pathology by reducing tau phosphorylation through regulating the expression level of GSK3-ß.


Subject(s)
Hydrogen Peroxide/adverse effects , Neurons/drug effects , Neuroprotective Agents/pharmacology , Rhodanine/analogs & derivatives , Thiazolidines/pharmacology , Cell Differentiation/drug effects , Cell Line, Tumor , Cell Survival/drug effects , DNA Damage/drug effects , Glycogen Synthase Kinase 3 beta/metabolism , Humans , Membrane Potential, Mitochondrial/drug effects , Neurons/metabolism , Neurons/pathology , Oxidative Stress/drug effects , Reactive Oxygen Species/metabolism , Rhodanine/pharmacology , Tretinoin/pharmacology , tau Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL